0000931059 false 0000931059 2021-09-07 2021-09-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











TO SECTION 13 or 15(d) OF THE



Date of report (Date of earliest event reported): September 7, 2021


Rennova Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)



(State or Other Jurisdiction of Incorporation)


001-35141   68-0370244


File Number)


(I.R.S. Employer

Identification No.)


400 South Australian Avenue, 8th Floor, West Palm Beach,
(Address of Principal Executive Offices)   (Zip Code)


(561) 855-1626
(Registrant’s Telephone Number, Including Area Code)




(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered under Section 12(b) of the Act:


Title of each class   Trading Symbol   Name of each exchange on which registered
None   None   None


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 1.01. Entry into a Material Definitive Agreement.


On September 7, 2021, Rennova Health, Inc. (the “Company”) entered into the Securities Purchase Agreement, dated as of September 7, 2021 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Purchase Agreement provides for the issuance of up to 1,100 shares of Series O Convertible Redeemable Preferred Stock (the “Series O Preferred Stock”) at two closings of 550 shares each. If all such shares of Series O Preferred Stock are issued, the Company will receive proceeds of $1,000,000.


The first closing will occur on September 8, 2021. The Company will issue 550 shares of Series O Preferred Stock and receive proceeds of $500,000. The second closing is expected to occur on or before October 5, 2021. The subsequent closing depends upon the Company’s satisfaction of certain conditions. There can be no assurance that the Company will satisfy all or any of these conditions or that the additional closing will take place. In addition, the Purchase Agreement restricts the Company’s use of any proceeds of the issuances of the Series O Preferred Stock, including to payroll and legal and accounting expenses.


The shares of Series O Preferred Stock will be issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and by Rule 506 of Regulation D promulgated thereunder as a transaction by an issuer not involving any public offering.


The terms of the Series O Preferred Stock were set forth in the Company’s Current Report on Form 8-K filed on May 11, 2021.


The foregoing description of the Purchase Agreement does not purport to be complete and is qualified by reference to the Purchase Agreement, a form of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 3.02. Unregistered Sales of Equity Securities.


The information set forth in Item 1.01 is incorporated herein by reference.


Item 8.01 Other Events.


As a result of conversions of shares of the Company’s preferred stock and the previously-announced Exchange Agreement between the Company and Christopher Diamantis, the Company currently has 262,350,000 shares of common stock issued and outstanding.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.   Exhibit Description
10.1   Form of Securities Purchase Agreement, dated as of September 7, 2021, among Rennova Health, Inc. and the investors signatory thereto
104    Cover Page Interactive Data File (embedded within the Inline XBRL document) 






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: September 8, 2021 RENNOVA HEALTH, INC.
  By: /s/ Seamus Lagan
    Seamus Lagan
    Chief Executive Officer
    (principal executive officer)